Early strength in the commodity market could not keep Canada’s main stock index in the green on Friday.

Ahead of a long weekend on Bay Street, high inflation and weakness in the latest manufacturing numbers could continued to keep investors on their toes and the TSX ended the week lower.

Despite a strong start, US indexes also closed sharply lower, though banks and megacap growth shares rose on the last day of a week that saw heightened volatility over concerns about the impact of higher inflation and rate hikes deployed to tame it. Retailers’ disappointing forecasts from major retailers didn’t help and only rattled market sentiment this week, proving that rising prices have started hurting consumers’ purchasing power.

Today in the Markets

TSX20,197.61+15.69TSX
 
TSXV702.09-3.49TSXV
 
CSE335.79+11.70TSXV
 
DJIA31,261.90+8.77DJIA
 
NASDAQ11,354.62-33.88NASDAQ
 
S&P 5003,901.36+0.57S&P 500
 

The Canadian dollar traded for 78.13 cents US compared to 78.11 cents US on Thursday.

Crude oil prices were down 0.01 to $112.20.

The price of gold was up 0.22 to $1,842.48.

In world markets, the Nikkei was up 336.19 points to 26,739.03 the Hang Seng was up 596.56 points to 20,717.24 the FTSE was up 87.24 points to 7,389.98, and the DAX was up 99.61 points to 13,981.91.

More From The Market Online
Innocan Pharma’s chief executive officer, Iris Bincovich

A Look into the Future of Chronic Pain Management

An interview with Innocan Pharma’s CEO, Iris Bincovich, about the company's innovative pain relief solutions.
AI generated stock image

Day trading vs. swing trading strategies for small-cap stocks

Investing in small-cap stocks can be lucrative, but requires clear understanding of different strategies, like day trading and swing trading.
Doctor with a bladder replica

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient’s Guide

As a patient with BCG-Unresponsive NMIBC CIS, bladder removal is far from the only option on the table in 2024.
Nervous system

NervGen Pharma: Proof that NVG-291 works?

Tantalizing anecdotal “evidence” has just been published suggesting that NervGen’s prospective wonder-drug, NVG-291, is delivering the goods.